Why Celldex Therapeutics Stock Is Moving After Its Latest Earnings Report

Celldex Therapeutics (CLDX) released second quarter and first half 2026 results, showing sharply lower revenue and a wider net loss. This earnings update is now central to how investors view the stock.

The earnings release comes after a strong run in Celldex Therapeutics' share price, with a 7 day share price return of 13.52% and a year to date share price return of 64.12%. The 1 year total shareholder return of 86.26% contrasts with a 5 year total shareholder return that is slightly negative. This suggests that recent momentum has picked up compared with the longer term record.

If this earnings move has you reassessing your watchlist, it may also be worth scanning for other potential healthcare opportunities through our curated set of 43 healthcare AI stocks.

Celldex Therapeutics now trades at a sizeable discount to both analyst targets and an estimated intrinsic value, even after the recent surge. Is the market rightly cautious about the widening losses, or is sentiment overshooting the fundamentals?

Preferred Price-to-Book Multiple of 4.9x for Celldex Therapeutics: Is It Justified?

Celldex Therapeutics closed at $44.33 with the stock described as expensive on a P/B basis, trading at 4.9x versus a 4.6x peer average and 2.5x for the broader US Biotechs industry.

The price to book ratio compares a company’s market value to its net assets. For early stage biopharma companies like Celldex Therapeutics that are still loss making, investors often watch P/B because earnings do not yet provide a clear benchmark. A higher P/B usually reflects expectations that the company’s pipeline and future cash flows will justify paying well above the value of current equity on the balance sheet.

For Celldex Therapeutics, the 4.9x P/B suggests the market is already pricing in a relatively rich premium to book value compared with peers. At the same time, the SWS DCF model indicates the stock is trading 61.1% below its estimated future cash flow value of $113.93 per share. This presents a very different signal compared with what the balance sheet based P/B multiple implies.

The 4.9x P/B is materially higher than both the 4.6x average for direct peers and the 2.5x average for the wider US Biotechs group. That gap indicates investors are assigning a higher valuation to Celldex Therapeutics’ assets than to many competitors, even though the company is still unprofitable and has reported growing losses over the past five years.

Result: Price-to-book of 4.9x (OVERVALUED).

However, Celldex Therapeutics still carries clear risks if clinical data on its antibody programs disappoints or if ongoing net losses pressure future funding options.

Another View on Celldex Therapeutics' Valuation

While Celldex Therapeutics looks expensive on a 4.9x P/B basis, the SWS DCF model presents a much lower implied valuation. At a recent price of $44.33, the stock sits 61.1% below an estimated future cash flow value of $113.93 per share. Which lens should carry more weight for you?

For a closer look at how this cash flow based estimate is built, including the assumptions behind it, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Celldex Therapeutics clearly mixed, it makes sense to review the full picture yourself and act while the latest information is fresh. To weigh the downside alongside the upside, start with the company’s 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Celldex Therapeutics?

If Celldex Therapeutics has your attention, do not stop there. Cast a wider net so you are not relying on a single story or sector.

• Spot potential upside early by checking out screener containing 20 high quality undiscovered gems that combine quality fundamentals with limited market attention.
• Strengthen your focus on resilience with the 85 resilient stocks with low risk scores that highlights companies scoring well on stability and risk controls.
• Target dependable businesses using the solid balance sheet and fundamentals stocks screener (50 results) that surfaces stocks with healthier finances to anchor your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.